Rubicon Organics Inc (ROMJ) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Rubicon Organics Inc C$0.39, price C$0.47, upside -15.9%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Rubicon Organics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Rubicon Organics Inc., together with its subsidiaries, engages in the production, processing, and sale of organic cannabis for the recreational and medical-use markets in Canada and internationally. The company offers cannabis products in dried flower, pre-rolls, concentrates, gummies, capsules, edibles, vapes, topicals, relief sticks, and oils.
Show more
Rubicon Organics Inc., together with its subsidiaries, engages in the production, processing, and sale of organic cannabis for the recreational and medical-use markets in Canada and internationally. The company offers cannabis products in dried flower, pre-rolls, concentrates, gummies, capsules, edibles, vapes, topicals, relief sticks, and oils. It sells its products under the Simply Bare Organic, 1964 Supply Co, Homestead Cannabis Supply, and Wildflower brand names. The company was formerly known as West Coast Land Corporation and changed its name to Rubicon Organics Inc. in May 2018. Rubicon Organics Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Stock analysis
Rubicon Organics Inc (ROMJ) currently trades at C$0.4650, while our model-based Fair Value estimate is C$0.3910, implying the stock looks roughly 18.9% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of C$0.7200 per share, and 5 of the 14 models we run sit above the C$0.4650 price.
Bear case: the Economic Profit group reads lowest at C$0.1300, and 9 of the 14 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Rubicon Organics Inc reported revenue of C$59.5M in FY2025 versus C$22.6M in FY2021, a compound +27.3%/yr. Reported net income was C$1.1M in FY2025.
Key figures
Market cap C$31.2M (≈ $22.1M) · P/S ratio 0.49 · EPS (TTM) C$−0.0100 · Net margin 1.8% · Return on equity −3.5% · Return on assets (EBIT) −6.1% · Operating margin −18.5% · Revenue (TTM) C$60.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −16%, ROMJ screens richer than that median.
Fair Value models
Bear C$0.3910Fair Value C$0.3910Bull C$0.3910
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+22.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+69.2%
’17
’18
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−127.7% (2020) → 3.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside−16% · Below median
Profitability
Return on assets−1% · Below median
Net margin (TTM)−2% · Below median
Operating margin (TTM)−18% · Bottom 25%
Growth and dividend
Revenue growth11% · Above median
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Rubicon Organics Inc (ROMJ) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of C$0.3910 versus a price of C$0.4650, about −16% upside (overvalued).
What is the fair value of ROMJ?
Our model-based fair value for Rubicon Organics Inc is C$0.3910 (as of Sep 23, 2026), built from audited fundamentals. The current price: C$0.4650.
What is the quality score of ROMJ?
Rubicon Organics Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rubicon Organics Inc (ROMJ)?
Our model-based price target is the fair value of C$0.3910 (as of Sep 23, 2026) from 14 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Rubicon Organics Inc stock forecast for 2026?
Our models put fair value at C$0.3910, about −16% upside versus a price of C$0.4650 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Rubicon Organics Inc (ROMJ)?
Rubicon Organics Inc reported trailing-twelve-month revenue of about C$60.8M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Rubicon Organics Inc (ROMJ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rubicon Organics Inc it is C$0.3910 per share (as of Sep 23, 2026), against a price of C$0.4650. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Rubicon Organics Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ROMJ trades above its calculated fair value: price C$0.4650, fair value C$0.3910, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ROMJ?
No. The price is what the market pays today (C$0.4650); the fair value is what the company's own numbers justify (C$0.3910). For Rubicon Organics Inc the two are C$0.0740 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rubicon Organics Inc worth?
The market values Rubicon Organics Inc at about C$31.2M (market capitalisation, as of Sep 23, 2026). Per share that is C$0.4650; our models calculate a fair value of C$0.3910 per share.
How solid is the balance sheet of Rubicon Organics Inc (ROMJ)?
Balance-sheet figures for Rubicon Organics Inc (as of Sep 23, 2026): return on equity −3.5%, debt of 0.24 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is ROMJ from its 52-week high?
Rubicon Organics Inc trades at C$0.4650, about 30% below its 52-week high of C$0.6600 and 11% above the low of C$0.4200 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.3910 is for.
Which stocks are comparable to Rubicon Organics Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rubicon Organics Inc stock attractive at the current price?
The data as of Sep 23, 2026: price C$0.4650, calculated fair value C$0.3910 (−16%), Quality Score 35/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ROMJ calculated?
We run Rubicon Organics Inc through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$0.3910, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Rubicon Organics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rubicon Organics Inc (ROMJ)?
The closing price on Sep 23, 2026 was C$0.4650. Our model-based fair value is C$0.3910, about −16% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rubicon Organics Inc right now?
The price sits above even our optimistic bull case (C$0.3910). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Rubicon Organics Inc
How large is the market capitalisation of Rubicon Organics Inc (ROMJ)?
The market capitalisation of Rubicon Organics Inc is C$31.2M (≈ $22.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rubicon Organics Inc (ROMJ)?
The price-to-sales ratio of Rubicon Organics Inc is 0.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rubicon Organics Inc (ROMJ)?
Earnings per share at Rubicon Organics Inc are C$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Rubicon Organics Inc (ROMJ)?
The net margin of Rubicon Organics Inc is 1.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rubicon Organics Inc (ROMJ)?
The return on equity (ROE) of Rubicon Organics Inc is −3.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rubicon Organics Inc (ROMJ)?
On an EBIT basis the return on assets of Rubicon Organics Inc is −6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rubicon Organics Inc (ROMJ)?
The operating margin of Rubicon Organics Inc is −18.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rubicon Organics Inc (ROMJ)?
Revenue at Rubicon Organics Inc is growing +10.6% versus a year earlier (3y avg +18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rubicon Organics Inc (ROMJ) generate?
The free cash flow of Rubicon Organics Inc is −C$11.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rubicon Organics Inc (ROMJ) carry?
The net debt of Rubicon Organics Inc is C$8.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Rubicon Organics Inc in the live analysis
One click puts Rubicon Organics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
